BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29895022)

  • 1. Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology.
    Adamczak M; Masajtis-Zagajewska A; Mazanowska O; Madziarska K; Stompór T; Więcek A
    Kidney Blood Press Res; 2018; 43(3):959-969. PubMed ID: 29895022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to the Treatment of Chronic Metabolic Acidosis in CKD.
    Raphael KL
    Am J Kidney Dis; 2016 Apr; 67(4):696-702. PubMed ID: 26776539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
    Goraya N; Simoni J; Jo CH; Wesson DE
    Kidney Int; 2014 Nov; 86(5):1031-8. PubMed ID: 24694986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.
    Harambat J; Kunzmann K; Azukaitis K; Bayazit AK; Canpolat N; Doyon A; Duzova A; Niemirska A; Sözeri B; Thurn-Valsassina D; Anarat A; Bessenay L; Candan C; Peco-Antic A; Yilmaz A; Tschumi S; Testa S; Jankauskiene A; Erdogan H; Rosales A; Alpay H; Lugani F; Arbeiter K; Mencarelli F; Kiyak A; Dönmez O; Drozdz D; Melk A; Querfeld U; Schaefer F;
    Kidney Int; 2017 Dec; 92(6):1507-1514. PubMed ID: 28729033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Serum Bicarbonate and CKD Progression in Children.
    Brown DD; Roem J; Ng DK; Reidy KJ; Kumar J; Abramowitz MK; Mak RH; Furth SL; Schwartz GJ; Warady BA; Kaskel FJ; Melamed ML
    Clin J Am Soc Nephrol; 2020 Jun; 15(6):755-765. PubMed ID: 32467307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic acidosis is associated with increased risk of adverse kidney outcomes and mortality in patients with non-dialysis dependent chronic kidney disease: an observational cohort study.
    Tangri N; Reaven NL; Funk SE; Ferguson TW; Collister D; Mathur V
    BMC Nephrol; 2021 May; 22(1):185. PubMed ID: 34011303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
    Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
    Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
    Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful correction of metabolic acidosis is difficult to achieve in chronic kidney disease.
    Caravaca-Fontán F; Díaz-Campillejo R; Valladares J; López Arnaldo C; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(3):328-335. PubMed ID: 31862183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study.
    Di Iorio BR; Bellasi A; Raphael KL; Santoro D; Aucella F; Garofano L; Ceccarelli M; Di Lullo L; Capolongo G; Di Iorio M; Guastaferro P; Capasso G;
    J Nephrol; 2019 Dec; 32(6):989-1001. PubMed ID: 31598912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
    Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
    J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
    Kittiskulnam P; Srijaruneruang S; Chulakadabba A; Thokanit NS; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Am J Nephrol; 2020; 51(1):24-34. PubMed ID: 31752000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).
    Gaggl M; Cejka D; Plischke M; Heinze G; Fraunschiel M; Schmidt A; Hörl WH; Sunder-Plassmann G
    Trials; 2013 Jul; 14():196. PubMed ID: 23826760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
    Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
    J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
    Bellasi A; Di Micco L; Santoro D; Marzocco S; De Simone E; Cozzolino M; Di Lullo L; Guastaferro P; Di Iorio B;
    BMC Nephrol; 2016 Oct; 17(1):158. PubMed ID: 27770799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis.
    Goraya N; Simoni J; Sager LN; Madias NE; Wesson DE
    Kidney Int; 2019 May; 95(5):1190-1196. PubMed ID: 30846270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Acidosis and CKD Progression.
    Madias NE
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):310-312. PubMed ID: 32769096
    [No Abstract]   [Full Text] [Related]  

  • 19. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis.
    Navaneethan SD; Shao J; Buysse J; Bushinsky DA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1011-1020. PubMed ID: 31196951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.